CJC-1295 (and the CJC-1295/Ipamorelin Stack) for Weight Loss: What the Evidence Shows

CJC-1295 is a long-acting synthetic analogue of growth-hormone-releasing hormone (GHRH) — the same mechanistic family as sermorelin and tesamorelin, but engineered to last far longer. The most-marketed version, CJC-1295 with DAC (Drug Affinity Complex), binds to albumin in the blood so its growth-hormone-stimulating effect stretches over days rather than minutes ^[1]. In anti-aging, bodybuilding, and “GH-optimization” clinics it is almost always sold stacked with ipamorelin, a separate ghrelin-receptor peptide, with bold body-recomposition and fat-loss claims attached. Here is the honest picture: neither CJC-1295 nor ipamorelin is FDA-approved for anything, both are sold as grey-market “research peptides,” and no published human randomized trial shows that CJC-1295, ipamorelin, or the combined stack causes weight loss — a PubMed search returns none. This is the deep-dive companion to our peptides for weight loss evidence review.

The honest summary

• Neither peptide is FDA-approved for any indication. CJC-1295 and ipamorelin are not approved drugs in the United States. They are sold as “research peptides” or compounded preparations, outside the FDA manufacturing and labeling system ^[1].
• No human trial shows the stack causes weight loss. A PubMed search for CJC-1295 or ipamorelin weight-loss or obesity randomized trials returns no study in which the peptide was given to people to lose weight and a weight outcome was measured. The fat-loss claim is unproven, not merely under-studied.
• The real human CJC-1295 data is a pharmacology study, not a diet trial. The best-known human study (Teichman 2006, Journal of Clinical Endocrinology & Metabolism) showed CJC-1295 raises growth hormone (GH) and IGF-1 for a prolonged period in healthy adults — it measured hormone levels, not weight loss ^[1].
• Its clinical development was halted. A phase 2 trial of CJC-1295 in HIV-associated visceral fat (lipodystrophy) was stopped after a participant died; the trial physician attributed the death to underlying coronary artery disease and considered it unrelated to the drug, but the program did not advance to approval ^[2].
• Raising GH and IGF-1 is not a validated weight-loss strategy. In adults who are not growth-hormone-deficient, pushing GH up carries real risks — insulin resistance, fluid retention (edema), joint symptoms, and sustained IGF-1 elevation — without a proven weight benefit ^[3].
• For weight loss, the evidence-based options are not GH peptides. The FDA-approved obesity drugs — semaglutide (STEP-1, −14.9%) and tirzepatide (SURMOUNT-1, −20.9%) — carry double-digit total-weight evidence from large randomized trials that the CJC-1295/ipamorelin stack simply does not have ^[4][5].

What CJC-1295 is and how it (and the ipamorelin stack) work

CJC-1295 is a synthetic peptide based on GHRH(1-29) — the active fragment of growth-hormone-releasing hormone — with chemical modifications that resist breakdown and, in the DAC version, attach it to blood albumin so it circulates for days ^[1]. Like its GHRH cousins sermorelin and tesamorelin, it works upstream: instead of injecting growth hormone, it prompts your own pituitary gland to release more of its own GH, which in turn raises insulin-like growth factor 1 (IGF-1). That GH/IGF-1 rise is what marketers point to when they claim fat loss.

Ipamorelin is a different kind of molecule — a selective growth-hormone secretagogue that acts on the ghrelin (GHS-R1a) receptor, a separate pathway from GHRH. Because the two act on different receptors, clinics pair them: the marketing logic is that CJC-1295 raises the baseline of GH release while ipamorelin adds a pulse, for a larger combined GH signal. That synergy is biologically plausible at the level of hormone secretion. What it is not is a tested weight-loss intervention — no trial has put the combination to that question in humans ^[6].

What the human evidence actually shows: pharmacology, not weight loss

The most cited human study of CJC-1295 is Teichman and colleagues (2006, Journal of Clinical Endocrinology & Metabolism). It was a pharmacology study: single subcutaneous doses of CJC-1295 in healthy adults produced sustained, dose-dependent increases in growth hormone and IGF-1, with the long-acting DAC version keeping IGF-1 elevated for over a week ^[1]. This is genuinely interesting endocrinology — it confirms the peptide does what it is designed to do at the hormone level. But it measured GH and IGF-1 concentrations and pharmacokinetics, not weight, body fat, or waist circumference. It is not a weight-loss trial, and it was never presented as one.

Beyond that pharmacology work, the published CJC-1295 literature is sparse and consists largely of narrative reviews of “research peptides,” analytical/anti-doping detection methods, and an ethnographic study of how the drug is bought and used off-label ^[2][6][7]. A PubMed search for CJC-1295 or ipamorelin weight-loss or obesity randomized controlled trials returns no human study designed to test, and measure, weight loss. When a compound has circulated in clinics for nearly two decades and still has zero weight-loss RCTs, the honest read is that the weight-loss claim is unsupported.

Why raising growth hormone is not a weight-loss plan

The whole premise of the CJC-1295/ipamorelin stack is that more growth hormone equals less fat. In adults who are genuinely GH-deficient, restoring GH can modestly shift body composition. But in people with normal GH axes — the population these clinics actually sell to — pushing GH and IGF-1 above the normal range is not a validated route to weight loss, and it carries real downsides. Sustained GH elevation can worsen insulin sensitivity and glucose tolerance, cause fluid retention and edema, and produce joint aches and carpal-tunnel-type symptoms; chronically raised IGF-1 is a theoretical concern in anyone with an undetected malignancy ^[3]. None of these risks is offset by proven weight loss.

CJC-1295/ipamorelin versus the drugs that actually have weight-loss evidence

The contrast is stark. Even tesamorelin — the only GHRH analogue with a registration-quality trial program — is approved solely for visceral fat in HIV, and it does not lower total body weight. The GLP-1 and GIP/GLP-1 agonists are built on large randomized trials with total body weight as the primary endpoint and double-digit results ^[4][5]. The CJC-1295/ipamorelin stack sits below all of them on the evidence ladder: no approval, no weight-loss RCT, a halted development program, and a pharmacology study standing in for clinical proof.

Safety, the grey market, and the compounding problem

• It is not an FDA-approved product. CJC-1295 and ipamorelin are sold as “research peptides” or compounded vials, with no FDA-verified purity, sterility, potency, or label. What is actually in the vial is not guaranteed ^[2].
• Raising GH and IGF-1 carries real risks. Reported and expected effects of GH-axis stimulation include injection-site reactions, flushing, headache, water retention and edema, joint pain, and impaired glucose tolerance; long-term IGF-1 elevation is poorly characterized in healthy adults ^[3].
• The clinical program never finished. CJC-1295 development was halted at phase 2 after a participant death (judged by the trial physician to reflect underlying coronary disease, not the drug) — so the long-term safety profile in humans was never established ^[2].
• It is not a substitute for an obesity medication. For chronic weight management, the FDA-approved, trial-validated options are the GLP-1/GIP agonists, prescribed and monitored by a clinician.

Bottom line

If you are looking at CJC-1295 or the CJC-1295/ipamorelin stack to lose weight, the evidence does not support it. Neither peptide is FDA-approved, no human trial shows the stack causes weight loss, the best human data is a GH/IGF-1 pharmacology study rather than a diet trial, and the drug's own development was halted at phase 2 ^[1][1][2]. Raising growth hormone in people who are not deficient is not a validated weight-loss strategy and carries metabolic risks ^[3]. For chronic weight management, the FDA-approved GLP-1 and GIP/GLP-1 agonists are the evidence-based tools ^[4][5]. For the full landscape of which peptides are real and which are hype, see our peptides for weight loss evidence review and the non-GLP-1 peptides for fat loss evidence check.

This article is educational and is not medical advice. Every claim above is anchored to a peer-reviewed source indexed in PubMed, verified against the live database before publication. CJC-1295 and ipamorelin have no FDA-approved product on the US market; do not source or self-administer compounded or grey-market peptides. Discuss any medication decision with your prescriber.